Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market definitions
1.3 Base estimates and calculations
1.4 Forecast calculations
1.5 Data sources
1.6 Data validation
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Cell & Gene Therapy Manufacturing Services industry 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Type trends
2.1.3 Mode trends
2.1.4 Indication trends
2.1.5 End-user trends
2.1.6 Regional trends
Chapter 3 Cell & Gene Therapy Manufacturing Services Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of cancer and other diseases
3.2.1.2 Increasing grants and investments for development of cell and gene therapies
3.2.1.3 Increasing pharmaceutical R&D spending
3.2.1.4 Technological advancements in cell & gene therapy technologies
3.2.2 Industry pitfalls & challenges
3.2.2.1 High risk of mutagenesis
3.2.2.2 Lack of standardized production systems for cell and gene therapy products
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By mode
3.3.3 By indication
3.3.4 By end-user
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Technology landscape
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Competitive dashboard, 2022
4.3 Company matrix analysis, 2022
4.4 Company market share analysis, 2022
4.5 Competitive positioning matrix, 2022
4.6 Strategic outlook matrix, 2022
Chapter 5 Cell & Gene Therapy Manufacturing Services Market Estimates and Forecast, By Type (USD Million)
5.1 Key trends, by type
5.2 Cell Therapy
5.2.1 Allogeneic
5.2.1.1 Mesenchymal stem cells
5.2.1.2 T-cells
5.2.1.3 Natural killer cells
5.2.1.4 Hematopoietic stem cells
5.2.1.5 Other allogeneic cells
5.2.2 Autologous
5.2.2.1 Mesenchymal stem cells
5.2.2.2 T-cells
5.2.2.3 Natural killer cells
5.2.2.4 Hematopoietic stem cells
5.2.2.5 Other autologous cells
5.3 Gene Therapy
5.3.1 Viral vectors
5.3.2 Non-viral vectors
Chapter 6 Cell & Gene Therapy Manufacturing Services Market Estimates and Forecast, By Mode (USD Million)
6.1 Key trends, by mode
6.2 Contract manufacturing
6.3 In-house manufacturing
Chapter 7 Cell & Gene Therapy Manufacturing Services Market Estimates and Forecast, By Indication (USD Million)
7.1 Key trends, by indication
7.2 Oncology diseases
7.3 Cardiovascular diseases
7.4 Orthopedic diseases
7.5 Infectious diseases
7.6 Ophthalmology diseases
7.7 Other indications
Chapter 8 Cell & Gene Therapy Manufacturing Services Market Estimates and Forecast, By End-user (USD Million)
8.1 Key trends, by end-user
8.2 Pharmaceutical and biotechnology companies
8.3 Academic and research institutes
8.4 Other end-users
Chapter 9 Cell & Gene Therapy Manufacturing Services Market Size and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 MEA
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Merck KGaA
10.2 F. Hoffmann-La Roche Ltd.
10.3 Boehringer Ingelheim
10.4 Cellular Therapeutics
10.5 Hitachi Chemical Co., Ltd.
10.6 Bluebird Bio Inc.
10.7 Takara Bio Inc.
10.8 Miltenyi Biotec
10.9 Thermo Fisher Scientific, Inc.
10.10 Samsung Biologics
